University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
Avatar

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of Resistance in R/R AML? What Are the Strategies to Combine IDH Inhibitors With SoC?

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Eytan Stein
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Eytan Stein
220 views
May 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
AML Biology and Treatment
20:35
University of Miami's 2nd Biennial Miami Leukemia Symposium

Curing APL in 2020: Have We Completely Deciphered Mechanism(s) of Co…

Feat. M. Tallman
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

Feat. E. Stein
20:28
University of Miami's 2nd Biennial Miami Leukemia Symposium

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding A…

Feat. M. Guzman
23:05
University of Miami's 2nd Biennial Miami Leukemia Symposium

Venetoclax Can Effectively Target AML Stem Cells Through Acid-Fueled…

Feat. D. Pollyea